Conditions: Alagille Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 versus placebo on the biochemical markers and pruritus associated with Alagille Syndrome.

Detailed description:

Arms:
arm 1: LUM001 administered orally once each day arm 2: Placebo administered orally once each day

Interventions: intervention 1: LUM001 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: